Life Sciences
BridgeBio to Present Phase 3 Encaleret Data at Boston Bone Meeting
The company's results in autosomal dominant hypocalcemia type 1 are scheduled for two oral presentations on October 11 at the Boston gathering.
BridgeBio Pharma, Inc.
Life Sciences
The company's results in autosomal dominant hypocalcemia type 1 are scheduled for two oral presentations on October 11 at the Boston gathering.